Drug development for neglected diseases: A deficient market and a public-health policy failure

Lancet

Volumn 359, Issue 9324, 2002, Pages 2188-2194

  Trouiller, Patrice ^a,f   Olliaro, Piero ^b,f   Torreele, Els ^c,f   Orbinski, James ^d,f   Laing, Richard ^e,f   Ford, Nathan ^f  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF TORONTO   (Canada)

^e BOSTON UNIVERSITY   (United States)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ARTEMETHER; ARTESUNATE; AZITHROMYCIN; CHLORPROGUANIL; DAPSONE; DEBUTYLHALOFANTRINE; DIETHYLCARBAMAZINE; DIHYDROARTEMISININ; EFLORNITHINE; ETAQUINE; FOSMIDOMYCIN; GATIFLOXACIN; IVERMECTIN; MILTEFOSINE; MOXIDECTIN; MOXIFLOXACIN; PRAZIQUANTEL; PYRONARIDINE; SITAMAQUINE; TAFENOQUINE; UNCLASSIFIED DRUG;

CANCER; CENTRAL NERVOUS SYSTEM DISEASE; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; INVESTMENT; LEISHMANIASIS; MALARIA; ONCHOCERCIASIS; PRIORITY JOURNAL; PROFIT; REVIEW; TROPICAL DISEASE; TUBERCULOSIS;

EID: 0037157590     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09096-7     Document Type: Article

References (35)

1. Access to essential drugs in poor countries: A lost battle?
2. Drug development output from 1975 to 1996: What proportion for tropical diseases?
3. The AIDS research model: Implications for other infectious diseases of global health importance
4. New drug development in the United States from 1963 to 1999
5. Drug treatment for tropical parasitic infections: Recent achievements and developments
6. Renewed strategies for drug development against parasitic diseases
7. R&D costs innovative output, and firm size in the pharmaceutical industry
8. Perspectives on stimulating industrial research and development for neglected infectious diseases
9. Orphan drug development: International program and study design issues
10. Is orphan drug status beneficial to tropical diseases control? Comparison of the American and future European orphan drug acts
11. Creating the costliest orphan: The Orphan Drug Act in the development of Ceredase
12. Inequalities in healthcare use and expenditures: Empirical data from eight developing countries and countries in transition
13. Risks in new drug development: Approval successes rates for investigational drugs
14. Innovation deficit revisited: Reflection on the productivity of pharmaceutical R&D
15. La Mutation du Marché Mondial des Vaccins
16. The case of pharmaceuticals
17. The new drug approvals of 1996, 1997, and 1998: Drug development trends in the user fee era
18. Global public-private partnerships, part II: What are the health issues for global governance?
19. Global public-private partnerships, part I: A new development in health?
20. Initial lessons from public-private partnerships in drug and vaccine development